Citations

Clear

3314 citation(s) found for "Do, Alexander".

Clinical longitudinal evaluation of COVID-19 patients and prediction of organ-specific recovery using artificial intelligence
Wang, Winston , Zhang, Charlotte L , Kang, Wei , Sang, Ye , Shen, Jun , Wang, Guangyu , Lozano, Alexander X.

Mayo Clinic

Precision Clinical Medicine | December 28, 2020 | Volume: 4 | Issue: 1 | Pages: 62-69

10.1093/pcmedi/pbaa040 | PMID 35693121 Get It

Abstract Within COVID-19 there is an urgent unmet need to predict at the time of hospital admission which COVID-19 patients will recover from the disease, and how fast they recover to deliver personalized treatments and to properly allocate hospital resources so that healthcare systems do not become overwhelmed. To this end, we have combined clinically salient CT imaging data synergistically with laboratory testing data in an integrative machine learning model to predict organ-specific recovery of patients from COVID-19. We trained and validated our model in 285 patients on each separate major organ system impacted by COVID-19 including the renal, pulmonary, immune, cardiac, and hepatic systems. To greatly enhance the speed and utility of our model, we applied an artificial intelligence method to segment and classify regions on CT imaging, from which interpretable data could be directly fed into the predictive machine learning model for overall recovery. Across all organ systems we achieved validation set area under the receiver operator characteristic curve (AUC) values for organ-specific recovery ranging from 0.80 to 0.89, and significant overall recovery prediction in Kaplan-Meier analyses. This demonstrates that the synergistic use of an artificial intelligence (AI) framework applied to CT lung imaging and a machine learning model that integrates laboratory test data with imaging data can accurately predict the overall recovery of COVID-19 patients from baseline characteristics.
Prospective validation of microseminoprotein‐β added to the 4Kscore in predicting high‐grade prostate cancer in an international multicentre cohort
Lonergan, Peter E. , Vertosick, Emily , Assel, Melissa , Sjoberg, Daniel D. , Haese, Alexander , Graefen, Markus , Boorjian, Stephen A. , Klee, George G., Pettersson, Kim , Routila, Erica , Vertosick, Emily A , Cooperberg, Matthew R , Pettersson, Kim , Vickers, Andrew J , Lilja, Hans , Lilja, Hans

Mayo Clinic

BJU International | December 25, 2020 | Volume: 128 | Issue: 2 | Pages: 218-224

10.1111/bju.15320 | PMID 33306251 Get It

Objectives To prospectively evaluate the performance of a pre‐specified statistical model based on four kallikrein markers in blood (total prostate‐specific antigen [PSA], free PSA, intact PSA, and human kallikrein‐related peptidase 2), commercially available as the 4Kscore, in predicting Gleason Grade Group (GG) ≥2 prostate cancer at biopsy in an international multicentre study at three academic medical centres, and whether microseminoprotein‐β (MSP) adds predictive value. Patients and Methods A total of 984 men were prospectively enrolled at three academic centres. The primary outcome was GG ≥2 on prostate biopsy. Three pre‐specified statistical models were used: a base model including PSA, age, digital rectal examination and prior negative biopsy; a model that added free PSA to the base model; and the 4Kscore. Results A total of 947 men were included in the final analysis and 273 (29%) had GG ≥2 on prostate biopsy. The base model area under the receiver operating characteristic curve of 0.775 increased to 0.802 with the addition of free PSA, and to 0.824 for the 4Kscore. Adding MSP to the 4Kscore model yielded an increase (0.014–0.019) in discrimination. In decision‐curve analysis of clinical utility, the 4Kscore showed a benefit starting at a 7.5% threshold. Conclusion A prospective multicentre evaluation of a pre‐specified model based on four kallikrein markers (4Kscore) with the addition of MSP improves the predictive discrimination for GG ≥2 prostate cancer on biopsy and could be used to inform biopsy decision‐making.
Same‐day opioid administration in opiate naïve patients is not associated with opioid‐induced esophageal dysfunction (OIED)
Balko, Ryan , Katzka, David A. , Alexander, Jeffrey A. , Mara, Kristin C. , Balko, Ryan A , Mara, Kristin C , Murray, Joseph A. , Ravi, Karthik

Mayo Clinic

Neurogastroenterology & Motility | December 22, 2020 | Volume: 33 | Issue: 5 | Pages: No page available

10.1111/nmo.14059 | PMID 33350541 Get It

AbstractBackgroundOpioid‐induced esophageal dysfunction (OIED) is a recognized complication of chronic opioid use. However, the impact of acute opioid administration on esophageal motility remains unclear.MethodsOpioid naïve patients with high‐resolution manometry (HRM) <480 min following esophagogastroduodenoscopy (EGD) (opioid‐HRM) and a control group with HRM <36 h prior to EGD between January 1, 2016, and November 10, 2018, from a single institution were identified. EGDs were performed exclusively with versed and fentanyl.Key ResultsOne hundred and seventy‐four patients were identified, with 83 (47.7%) opioid‐HRM and 91 (52.3%) controls. Mean time from EGD to HRM was 229 (78–435) min. Baseline clinical features and HRM indications were similar between opioid‐HRM and controls. Chicago classification v3.0 defined HRM findings were similar between groups. Major motility disorders as defined by the Chicago classification v3.0 occurred at a similar frequency among opioid‐HRM and controls (27.7% vs. 36.3%, p = 0.23). Mean distal contractile integrity (DCI) was higher in opioid‐HRM (1939.3 ± 1318.9 vs. 1792.2 ± 2062.3 mmHg∙cm∙s, p = 0.043), but maximum DCI, distal latency, and integrated relaxation pressure did not differ between groups. Subgroup analysis assessing time and dose dependency did not identify differences in individual manometric parameters and Chicago classification v3.0 diagnosis between patients with HRM <240 min after EGD, >240 min after EGD, ≥125 mcg of IV fentanyl, <125 mcg IV fentanyl and controls.Conclusions and InferencesSame‐day acute opioid administration did not affect HRM findings in opioid naïve patients. Studies assessing the pathophysiology of and duration‐dependent relationship with opioids in OIED are needed.
1098: International Participant Satisfaction With the CERTAIN Structured Approach to Acute Care
Sun, Yuqiang, Heise, Katherine J., Gajić, Ognjen, Dong, Yue, Tekin, Aysun , Kashyap, Rahul , Niven, Alexander S. , Gajic, Ognjen

Mayo Clinic

Critical Care Medicine | December 18, 2020 | Volume: 49 | Issue: 1 | Pages: 550-550

10.1097/01.ccm.0000730280.27054.9e Get It

Aerosol Generation From a Simulated Air Leak
Lee, Augustine S. , Patel, Neal M. , Helgeson, Scott A. , Lim, Kaiser G. , Niven, Alexander S.

Mayo Clinic

Journal of Bronchology & Interventional Pulmonology | December 15, 2020 | Volume: 28 | Issue: 1 | Pages: 73-75

10.1097/lbr.0000000000000710 | PMID 33332846 Get It

Chronic Histologic Changes Are Present Regardless of HLA Mismatches: Evidence from HLA-Identical Living Donor Kidney Transplants
D’Costa, Matthew R. , Bentall, Andrew , Đenić, Aleksandar , Merzkani, Massini , Ryan, Margaret , Alexander, Mariam P., Gandhi, Manish J. , Ryan, Margaret S, D'Costa, Matthew , Denic, Aleksandar , Bentall, Andrew , Schinstock, Carrie A. , Park, Walter D. , Smith, Byron H. , Stegall, Mark D.

Mayo Clinic

Transplantation | December 14, 2020 | Volume: 105 | Issue: 11 | Pages: e244-e256

10.1097/tp.0000000000003579 | PMID 33315759 Get It

Background. At 5 and 10 y after kidney transplantation, chronic histologic changes such as arteriolar hyalinosis and mesangial expansion are common; however, determining cause is difficult. We compared surveillance biopsies in living donor kidney transplants (LDKTx) from HLA-matched siblings (termed HLA-identical [HLA-ID]) with HLA non-ID to investigate which histologic changes were likely due to alloimmune injury and which were due to nonalloimmune injury. Methods. We performed a retrospective, cohort study comparing HLA-ID sibling LDKTx (n = 175) with HLA non-ID LDKTx (n = 175; matched for age, sex, and year of transplant ±2 y) performed at a single institution from March 1999 to November 2018. Results. Baseline characteristics and maintenance immunosuppression were similar. Mortality rates were similar, but in the HLA-ID group, 10-y death-censored graft survival was higher (93.8% versus 80.9% HLA non-ID LDKTx; P < 0.001), rejection rates were lower (after 1 y 9.6% versus 27.1%; P < 0.001), and Banff inflammation scores including glomerulitis and peritubular capillaritis were lower on surveillance biopsies at 1, 5, and 10 y. In contrast, chronic Banff scores (interstitial fibrosis, arteriolar hyalinosis, mesangial expansion, etc) were similar in prevalence and severity on surveillance biopsies at 1, 5, and 10 y. Conclusions. HLA-ID LDKTx have less inflammation and less transplant glomerulopathy, but most chronic histologic changes were similar to less well-matched LDKTx. We conclude that these types of chronic changes are not associated with HLA mismatches and may be due to nonimmunologic causes (hypertension, obesity, etc), suggesting that new management approaches to prevent these lesions may be needed.
Burden of arrhythmia in hospitalized HIV patients
Abudan, Anas , Vaidya, Vaibhav R. , Tripathi, Byomesh , Noseworthy, Peter A. , DeSimone, Daniel C. , Egbe, Alexander , Arora, Shilpkumar , Sridhar, Haarini , DeSimone, Christopher V. , Mulpuru, Siva K. , Deshmukh, Abhishek , Abudan, Anas A , Mulpuru, Siva K , Deshmukh, Abhishek J , Tripathi, Byomesh , Noseworthy, Peter A , DeSimone, Christopher V , DeSimone, Daniel C

Mayo Clinic

Clinical Cardiology | December 10, 2020 | Volume: 44 | Issue: 1 | Pages: 66-77

10.1002/clc.23506 | PMID 33295667 Get It

AbstractBackgroundThe improved life expectancy observed in patients living with human immunodeficiency virus (HIV) infection has made age‐related cardiovascular complications, including arrhythmias, a growing health concern.HypothesisWe describe the temporal trends in frequency of various arrhythmias and assess impact of arrhythmias on hospitalized HIV patients using the Nationwide Inpatient Sample (NIS).MethodsData on HIV‐related hospitalizations from 2005 to 2014 were obtained from the NIS database using International Classification of Diseases, 9th Revision (ICD‐9) codes. Data was further subclassified into hospitalizations with associated arrhythmias and those without. Baseline demographics and comorbidities were determined. Outcomes including in‐hospital mortality, cost of care, and length of stay were extracted. SAS 9.4 (SAS Institute Inc., Cary, NC) was utilized for analysis. A multivariable analysis was performed to identify predictors of arrhythmias among hospitalized HIV patients.ResultsAmong 2 370 751 HIV‐related hospitalizations identified, the overall frequency of any arrhythmia was 3.01%. Atrial fibrillation (AF) was the most frequent arrhythmia (2110 per 100 000). The overall frequency of arrhythmias increased over time by 108%, primarily due to a 132% increase in AF. Arrhythmias are more frequent among older males, lowest income quartile, and nonelective admissions. Patients with arrhythmias had a higher in‐hospital mortality rate (9.6%). In‐hospital mortality among patients with arrhythmias decreased over time by 43.8%. The cost of care and length of stay associated with arrhythmia‐related hospitalizations were mostly unchanged.ConclusionsArrhythmias are associated with significant morbidity and mortality in hospitalized HIV patients. AF is the most frequent arrhythmia in hospitalized HIV patients.
Germline variation in the insulin-like growth factor pathway and risk of Barrett’s esophagus and esophageal adenocarcinoma
Dighe, Shruti , Chen, Jianhong , Yan, Li , Gharahkhani, Puya , Onstad, Lynn , Levine, David , Palles, Claire , Ye, Weimin , Gammon, Marilie D. , Iyer, Prasad G. , Anderson, Lesley , Liu, Geoffrey , Wu, Anna H. , Chow, Wong‐Ho , Lagergren, Jesper , Shaheen, Nicholas J. , Corley, Douglas A. , Prenen, Hans , MacDonald, David , Barr, Hugh , Love, Sharon , Chegwidden, Laura , Attwood, Stephen E., Harrison, Rebecca , Ott, Katja , Moebus, Susanne , Lang, Hauke , Mayershofer, Rupert , Knapp, Michael , Veits, Lothar , Gerges, Christian , Weismüller, Josef , Vashist, Yogesh K. , Nöthen, Markus M. , Izbicki, Jakob R. , Manner, Hendrik , Neuhaus, Horst , Böhmer, Anne C. , Hölscher, Arnulf H. , Anders, Mario , Pech, Oliver , Schumacher, Brigitte , Noder, Tania , Lorenz, Dietmar , Vieth, Michael , May, Andrea , Hess, Timo , Kreuser, Nicole , Becker, Jessica , Ell, Christian , Moysich, Kirsten B. , MacGregor, Stuart , Tomlinson, Ian , Whiteman, David C. , Schumacher, Johannes , Vaughan, Thomas L. , Madeleine, Margaret M. , Hardie, Laura J. , Buas, Matthew F. , Moysich, Kirsten , Nöthen, Markus M , Liu, Geoffrey , Gharahkhani, Puya , MacGregor, Stuart , Lagergren, Jesper , Hardie, Laura J , Anderson, Lesley A , Ye, Weimin , Love, Sharon B , Prenen, Hans , Moebus, Susanne , Hess, Timo , Palles, Claire , Whiteman, David C , Buas, Matthew F , He, Qianchuan , Dai, James Y. , Risch, Harvey A. , Bernstein, Leslie , Caestecker, John de , MacDonald, David, Moayyedi, Paul , Watson, Peter J. , Venerito, Marino , Gockel, Ines , Rösch, Thomas , Anders, Mario , Schmidt, Claudia , Schmidt, Thomas , Ambrosone, Christine B. , Jankowski, Janusz

Mayo Clinic

Carcinogenesis | December 9, 2020 | Volume: 42 | Issue: 3 | Pages: 369-377

10.1093/carcin/bgaa132 | PMID 33300568 Get It

Abstract Genome-wide association studies (GWAS) of esophageal adenocarcinoma (EAC) and its precursor, Barrett’s esophagus (BE), have uncovered significant genetic components of risk, but most heritability remains unexplained. Targeted assessment of genetic variation in biologically relevant pathways using novel analytical approaches may identify missed susceptibility signals. Central obesity, a key BE/EAC risk factor, is linked to systemic inflammation, altered hormonal signaling and insulin-like growth factor (IGF) axis dysfunction. Here, we assessed IGF-related genetic variation and risk of BE and EAC. Principal component analysis was employed to evaluate pathway-level and gene-level associations with BE/EAC, using genotypes for 270 single-nucleotide polymorphisms (SNPs) in or near 12 IGF-related genes, ascertained from 3295 BE cases, 2515 EAC cases and 3207 controls in the Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON) GWAS. Gene-level signals were assessed using Multi-marker Analysis of GenoMic Annotation (MAGMA) and SNP summary statistics from BEACON and an expanded GWAS meta-analysis (6167 BE cases, 4112 EAC cases, 17 159 controls). Global variation in the IGF pathway was associated with risk of BE (P = 0.0015). Gene-level associations with BE were observed for GHR (growth hormone receptor; P = 0.00046, false discovery rate q = 0.0056) and IGF1R (IGF1 receptor; P = 0.0090, q = 0.0542). These gene-level signals remained significant at q &lt; 0.1 when assessed using data from the largest available BE/EAC GWAS meta-analysis. No significant associations were observed for EAC. This study represents the most comprehensive evaluation to date of inherited genetic variation in the IGF pathway and BE/EAC risk, providing novel evidence that variation in two genes encoding cell-surface receptors, GHR and IGF1R, may influence risk of BE.
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease
Rhee, Frits van , Oksenhendler, Éric , Srkalović, Gordan , Voorhees, Peter M. , Lim, Megan S. , Ide, Makoto , Parente, Sophia A. T. , Schey, Stephen, Streetly, Matthew , Wu, David , Brandstadter, Joshua D. , Munshi, Nikhil C. , Bowne, Wilbur B. , Elenitoba‐Johnson, Kojo S.J. , Lechowicz, Mary Jo , Chandrakasan, Shanmuganathan , Pierson, Sheila K. , Greenway, Amy D, Yoshizaki, Kazuyuki , Chadburn, Amy , van Rhee, Frits , Ide, Makoto , Lim, Megan S , Chandrakasan, Shanmuganathan , Dispenzieri, Angela , Wong, Raymond , Maillard, Ivan P. , Fosså, Alexander , Nasta, Sunita , Kurzrock, Razelle , Uldrick, Thomas S. , Casper, Corey , Fajgenbaum, David C.

Mayo Clinic

Blood Advances | December 9, 2020 | Volume: 4 | Issue: 23 | Pages: 6039-6050

10.1182/bloodadvances.2020003334 | PMID 33284946 Get It

Abstract Castleman disease (CD) includes a group of rare and heterogeneous disorders with characteristic lymph node histopathological abnormalities. CD can occur in a single lymph node station, which is referred to as unicentric CD (UCD). CD can also involve multicentric lymphadenopathy and inflammatory symptoms (multicentric CD [MCD]). MCD includes human herpesvirus-8 (HHV-8)–associated MCD, POEMS-associated MCD, and HHV-8−/idiopathic MCD (iMCD). The first-ever diagnostic and treatment guidelines were recently developed for iMCD by an international expert consortium convened by the Castleman Disease Collaborative Network (CDCN). The focus of this report is to establish similar guidelines for the management of UCD. To this purpose, an international working group of 42 experts from 10 countries was convened to establish consensus recommendations based on review of treatment in published cases of UCD, the CDCN ACCELERATE registry, and expert opinion. Complete surgical resection is often curative and is therefore the preferred first-line therapy, if possible. The management of unresectable UCD is more challenging. Existing evidence supports that asymptomatic unresectable UCD may be observed. The anti–interleukin-6 monoclonal antibody siltuximab should be considered for unresectable UCD patients with an inflammatory syndrome. Unresectable UCD that is symptomatic as a result of compression of vital neighboring structures may be rendered amenable to resection by medical therapy (eg, rituximab, steroids), radiotherapy, or embolization. Further research is needed in UCD patients with persisting constitutional symptoms despite complete excision and normal laboratory markers. We hope that these guidelines will improve outcomes in UCD and help treating physicians decide the best therapeutic approach for their patients.
The Military Orthopedics Tracking Injuries and Outcomes Network: A Solution for Improving Musculoskeletal Care in the Military Health System
Mauntel, Timothy C. , Freedman, Brett A. , Provencher, Matthew T. , Tokish, John M. , Lee, Ian E, Bailey, James R. , Burns, Travis C. , Cameron, Kenneth L. , Grenier, Eric, Haley, Chad A., McDonald, Lucas S. , Pallis, Mark, Posner, Matthew, Rivera, Jessica C. , Roach, Christopher J, Robins, Richard J. , Sheean, Andrew J. , Slabaugh, Mark A. , Volk, William R., Dickens, Jonathan F. , Dickens, Jonathan F , Tenan, Matthew S. , Potter, Benjamin Kyle , Provencher, Matthew T. , Rhon, Daniel I. , LeClere, Lance E. , Owens, Brett D. , Roach, Christopher J, Schmitz, Matthew R.

Mayo Clinic

Military Medicine | December 6, 2020 | Volume: 187 | Issue: 3-4 | Pages: e282-e289

10.1093/milmed/usaa304 | PMID 33242087 Get It

Abstract Introduction Musculoskeletal injuries are an endemic amongst U.S. Military Service Members and significantly strain the Department of Defense’s Military Health System. The Military Health System aims to provide Service Members, military retirees, and their families the right care at the right time. The Military Orthopedics Tracking Injuries and Outcomes Network (MOTION) captures the data that can optimize musculoskeletal care within the Military Health System. This report provides MOTION structural framework and highlights how it can be used to optimize musculoskeletal care. Materials and Methods MOTION established an internet-based data capture system, the MOTION Musculoskeletal Data Portal. All adult Military Health System patients who undergo orthopedic surgery are eligible for entry into the database. All data are collected as routine standard of care, with patients and orthopedic surgeons inputting validated global and condition-specific patient reported outcomes and operative case data, respectively. Patients have the option to consent to allow their standard of care data to be utilized within an institutional review board approved observational research study. MOTION data can be merged with other existing data systems (e.g., electronic medical record) to develop a comprehensive dataset of relevant information. In pursuit of enhancing musculoskeletal injury patient outcomes MOTION aims to: (1) identify factors which predict favorable outcomes; (2) develop models which inform the surgeon and military commanders if patients are behind, on, or ahead of schedule for their targeted return-to-duty/activity; and (3) develop predictive models to better inform patients and surgeons of the likelihood of a positive outcome for various treatment options to enhance patient counseling and expectation management. Results This is a protocol article describing the intent and methodology for MOTION; thus, to date, there are no results to report. Conclusions MOTION was established to capture the data that are necessary to improve military medical readiness and optimize medical resource utilization through the systematic evaluation of short- and long-term musculoskeletal injury patient outcomes. The systematic enhancement of musculoskeletal injury care through data analyses aligns with the National Defense Authorization Act (2017) and Defense Health Agency’s Quadruple Aim, which emphasizes optimizing healthcare delivery and Service Member medical readiness. This transformative approach to musculoskeletal care can be applied across disciplines within the Military Health System.